title: CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
abstract: The goal of this review is to provide historical, recent preclinical, and current clinical summaries of efforts to understand the CD38 molecule and to develop monoclonal antibodies that target it. We focus particularly on efforts involving multiple myeloma, a malignancy of terminally differentiated B cells that remains incurable despite many advances. An era of anti-CD38 monoclonal antibody therapy for myeloma is approaching, one that, we hope, will enable patients to live longer and better lives.
authors.affiliation: Departments of Medicine and Pathology and the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA. Electronic address: Swong7@tuftsmedicalcenter.org.
authors.forename: Sandy W
authors.initials: SW
authors.lastname: Wong
authors.affiliation: Departments of Medicine and Pathology and the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA.
authors.forename: Raymond L
authors.initials: RL
authors.lastname: Comenzo
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D051997:ADP-ribosyl Cyclase 1
keywords: Anti-CD38; CD38; Immunotherapy; Monoclonal antibody; Multiple myeloma